N-{1-(1,4-dioxaspiro[4.5]dec-8-yl)-2-[4-(2-methylquinolin-4-ylmethoxy)benzenesulfonyl]ethyl}-N-hydroxyformamide | 502607-99-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-{1-(1,4-dioxaspiro[4.5]dec-8-yl)-2-[4-(2-methylquinolin-4-ylmethoxy)benzenesulfonyl]ethyl}-N-hydroxyformamide
• 英文别名: N-{1-(1,4-Dioxa-spiro[4.5]dec-8-yl)-2-[4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonyl]-ethyl}-N-hydroxy-formamide；N-[1-(1,4-dioxaspiro[4.5]decan-8-yl)-2-[4-[(2-methylquinolin-4-yl)methoxy]phenyl]sulfonylethyl]-N-hydroxyformamide
• CAS: 502607-99-0
• 化学式: C₂₈H₃₂N₂O₇S
• 分子量: 540.637
• InChiKey: IDKUTWZTCGVYET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  124
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-{1-(1,4-dioxaspiro[4.5]dec-8-yl)-2-[4-(2-methylquinolin-4-ylmethoxy)benzenesulfonyl]ethyl}-N-hydroxyformamide 在 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 24.0h， 以84.5%的产率得到N-Hydroxy-N-{2-[4-(2-methylquinolin-4-ylmethoxy)benzenesulfonyl]-1-(4-oxocyclohexyl)ethyl}formamide
  参考文献：
  名称：

  REVERSE HYDROXAMIC ACID DERIVATIVES

  摘要：

  公开号：

  EP1431285B1
• 作为产物：
  描述：

  在 sodium tetrahydroborate 、 羟胺 、 乙酸酐 、 溶剂黄146 、 甲基磺酰氯 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 N-{1-(1,4-dioxaspiro[4.5]dec-8-yl)-2-[4-(2-methylquinolin-4-ylmethoxy)benzenesulfonyl]ethyl}-N-hydroxyformamide
  参考文献：
  名称：

  Reverse hydroxamate-based selective TACE inhibitors

  摘要：

  Reverse hydroxamate-based selective TACE inhibitors are described. They have potent TACE inhibitory activities and excellent selectivities against MMP-1, 2, 3, 8, 9, 13, 14, and 17. One representative compound, 18 has demonstrated an excellent oral inhibitory activity of the lipopolysaccharide (LPS)-stimulated TNF-alpha production in rats. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.048

文献信息

• Reverse hydroxamic acid derivatives
  申请人：——

  公开号：US20040242928A1

  公开（公告）日：2004-12-02

  Reverse hydroxamic acid derivatives having specific structure represented by a general formula (Ia): 1 (wherein A is a hydrogen atom or the like; Ar 1 is an arylene or the like; Ar 2 is an optionally substituted aryl, a heteroaryl or the like; R 1 is a hydrogen atom, an alkyl or the like; R 2a is a substituted cycloaryl, a heterocycloaryl or the like) and a general formula (I): 2 (wherein A, Ar 1 , Ar 2 , and R 1 are the same as defined above and R 2 is an hydrogen atom, R 2a or the like) and salts thereof, which have TNF-&agr; converting enzyme (TACE) inhibitory activity.

  具有特定结构的反式羟胺酸衍生物，通式（Ia）表示如下：1（其中A是氢原子或类似物；Ar1是芳烃或类似物；Ar2是可选取代的芳基、杂环芳基或类似物；R1是氢原子、烷基或类似物；R2a是取代的环烷基、杂环环烷基或类似物），以及通式（I）2（其中A、Ar1、Ar2和R1的定义与上述相同，而R2是氢原子、R2a或类似物），以及其盐，具有TNF-α转化酶（TACE）抑制活性。
• US7511144B2
  申请人：——

  公开号：US7511144B2

  公开（公告）日：2009-03-31
• REVERSE HYDROXAMIC ACID DERIVATIVES
  申请人：KAKEN PHARMACEUTICAL CO., LTD.

  公开号：EP1431285B1

  公开（公告）日：2009-01-07
• Reverse hydroxamate-based selective TACE inhibitors
  作者：Noriyuki Kamei、Tomohiro Tanaka、Kentaro Kawai、Kyosei Miyawaki、Akihiko Okuyama、Yoshiko Murakami、Yoshio Arakawa、Makoto Haino、Tatsuhiro Harada、Masanao Shimano

  DOI：10.1016/j.bmcl.2004.03.048

  日期：2004.6

  Reverse hydroxamate-based selective TACE inhibitors are described. They have potent TACE inhibitory activities and excellent selectivities against MMP-1, 2, 3, 8, 9, 13, 14, and 17. One representative compound, 18 has demonstrated an excellent oral inhibitory activity of the lipopolysaccharide (LPS)-stimulated TNF-alpha production in rats. (C) 2004 Elsevier Ltd. All rights reserved.